86259-87-2 Usage
Description
2-[2-[2-[2-(BENZYLOXY)ETHOXY]ETHOXY]ETHOXY]ETHANOL, also known as Benzyl-PEG5-alcohol, is a PEG (polyethylene glycol) linker with an acid-labile benzyl group and a reactive primary alcohol. The hydroxyl group allows for further derivatization of the compound, while the hydrophilic PEG linker enhances its water solubility in aqueous media.
Uses
Used in Pharmaceutical Industry:
2-[2-[2-[2-(BENZYLOXY)ETHOXY]ETHOXY]ETHOXY]ETHANOL is used as a pharmaceutical intermediate for the synthesis of various drug conjugates and prodrugs. The acid-labile benzyl group enables controlled drug release under specific conditions, while the PEG linker improves the solubility and stability of the drug molecules.
Used in Bioconjugation:
In the field of bioconjugation, 2-[2-[2-[2-(BENZYLOXY)ETHOXY]ETHOXY]ETHOXY]ETHANOL serves as a versatile linker for attaching biologically active molecules, such as peptides, proteins, or nucleic acids, to other molecules or surfaces. The reactive primary alcohol group allows for covalent attachment, while the PEG linker provides steric stabilization and reduces immunogenicity.
Used in Drug Delivery Systems:
2-[2-[2-[2-(BENZYLOXY)ETHOXY]ETHOXY]ETHOXY]ETHANOL is utilized in the development of drug delivery systems, such as nanoparticles, liposomes, or hydrogels, to improve the bioavailability, targeting, and controlled release of therapeutic agents. The hydrophilic PEG linker enhances the stability and circulation time of the drug delivery systems in the body.
Used in Chemical Synthesis:
In chemical synthesis, 2-[2-[2-[2-(BENZYLOXY)ETHOXY]ETHOXY]ETHOXY]ETHANOL acts as a building block for the creation of more complex molecules with specific properties. The reactive primary alcohol group allows for further functionalization, enabling the synthesis of a wide range of compounds for various applications, such as materials science, diagnostics, or therapeutics.
Check Digit Verification of cas no
The CAS Registry Mumber 86259-87-2 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 8,6,2,5 and 9 respectively; the second part has 2 digits, 8 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 86259-87:
(7*8)+(6*6)+(5*2)+(4*5)+(3*9)+(2*8)+(1*7)=172
172 % 10 = 2
So 86259-87-2 is a valid CAS Registry Number.
InChI:InChI=1/C15H24O5/c16-6-7-17-8-9-18-10-11-19-12-13-20-14-15-4-2-1-3-5-15/h1-5,16H,6-14H2
86259-87-2Relevant articles and documents
Naloxegol Oxalate and Solid Dispersion thereof
-
Paragraph 0126, (2021/11/05)
The present invention relates to solid dispersion of Naloxegol oxalate. Further, the present invention relates to an improved process for Naloxegol oxalate and intermediates thereof.
Optimization of IEDDA bioorthogonal system: Efficient process to improve trans-cyclooctene/tetrazine interaction
Béquignat, Jean-Baptiste,Boucheix, Claude,Canitrot, Damien,Chezal, Jean-Michel,Degoul, Fran?oise,Miot-Noirault, Elisabeth,Moreau, Emmanuel,Navarro-Teulon, Isabelle,Quintana, Mercedes,Rondon, Aurélie,Taiariol, Ludivine,Ty, Nancy
supporting information, (2020/07/21)
The antibody pretargeting approach for radioimmunotherapy (RIT) using inverse electron demand Diels-Alder cycloaddition (IEDDA) constitutes an emerging theranostic approach for solid cancers. However, IEDDA pretargeting has not reached clinical trial. The major limitation of the IEDDA strategy depends largely on trans-cyclooctene (TCO) stability. Indeed, TCO may isomerize into the more stable but unreactive cis-cyclooctene (CCO), leading to a drastic decrease of IEDDA efficiency. We have thus developed both efficient and reproducible synthetic pathways and analytical follow up for (PEGylated) TCO derivatives, providing high TCO isomeric purity for antibody modification. We have set up an original process to limit the isomerization of TCO to CCO before the mAbs’ functionalization to allow high TCO/tetrazine cycloaddition.
SUPRAMOLECULAR PROTEIN ASSEMBLIES WITH ADVANCED FUNCTIONS AND SYNTHESIS THEREOF
-
Paragraph 0462-0463, (2019/05/18)
The present invention discloses stimuli-sensitive protein conjugate which can make supramolecular protein assemblies and methods for using the same. The present invention provides simple and rational process for construction of said stimuli-sensitive spherical protein assemblies through supramolecular chemical strategy.
